Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Johnson & Johnson says it has identified a lead vaccine candidate for the new coronavirus that it will develop in partnership with the US Biomedical Advanced Research and Development Authority (BARDA). J&J began developing the vaccine in January, as soon as the virus’s sequence became available. The firm says it and BARDA are willing to spend more than $1 billion to get the adenoviral vaccine into human clinical studies by September and available for emergency use in early 2021.
This article has been sent to the following recipient: